TWI235060B - Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia - Google Patents
Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia Download PDFInfo
- Publication number
- TWI235060B TWI235060B TW090122228A TW90122228A TWI235060B TW I235060 B TWI235060 B TW I235060B TW 090122228 A TW090122228 A TW 090122228A TW 90122228 A TW90122228 A TW 90122228A TW I235060 B TWI235060 B TW I235060B
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- group
- benzenesulfonamide
- trifluoromethyl
- pyrazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
1235060 A7 B7
五、發明説明(1 本發明係於預防及、、Λ益、 說,本發明係關於使用=形成的範圍中, 及治療瘤形成。 ㈣抑制劑或其衍生物於預防 發明背景 角作。?抑制前列腺素產生方面扮演重要 物的-致目標。然2而」產已為發明抗發炎藥 與發炎作时關之腫脹;素引起之疼痛及 (NSAID,S) n A u 1P非類固醇抗發炎藥物 UJ:: 炎作用的前列腺素調節作用 物會產生嚴重的副作用,包括二t類固每抗發炎藥 ,· G括致叩的潰瘍,如此限制並户 療潛力。非類固醇抗發炎藥物以外另一 八 脂酮,其亦會產生;^_ 、為使用皮質 時。 特別具當長期治療進行 非類固醇抗發炎藥物已被發現係藉由抑制人類花生 酸/前列腺素途徑,包括環氧酶(cox),以 生產。最近發現的與發«關之謂發料(名為"環= 2(C〇X-2),,或,,前列腺素G/H合成酶π 衣虱峙一 •供了 >個可右* 的抑制目標,較有效地減輕發炎且產生 副作用。 1較不強烈的 卜比嗅小基]苯料胺已被認為環氧酶_2抑制劑,a
臨床及臨床試驗中均被證實對發炎、關r ^,J P炎和疼痛的治恭 副作用最小。其用於預防大腸癌亦已在美國專利案Ϊ -4-
本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1235060 A7 B7 五、發明説明 5,466,823號中述及。然而,其用於治療大腸癌或用於治療 或預防其它瘤形成,先前並未敘述。 本發明係針對使用環氧酶_2抑制劑於治療及預防上皮細 胞衍生瘤形成。 發明詳細說明 本發明提供-種治療或預防上皮細胞衍生瘤形成的方法 給需要該治療或預防的受實驗者,該方法包含給予受實驗 者治療有效量的環氧酶-2抑制劑或其衍生物。 名詞,,治療”包括部份或全部抑制新生瘤生長、蔓延或轉 移,以及部份或全部摧毀新生瘤細胞。 名詞’’預防”包括完全預防臨床明顯瘤形成的開始,或預 防有危險的人發生前臨床明顯期瘤形成。預防惡性細胞起 始,或抑制或反轉由前惡性細胞到惡性細胞的進程,亦定 義於内。其包括預防治療有發展新生瘤危險的人。 名詞”治療有效的,,意指使每個作用物的量能適宜,使達 成改善病況的目標及改善作用物本身在治療過程中發生意 外的頻率,並避免另類治療伴隨的不利影響。 用於治療目的的名詞"受實驗者"包含任何接受實驗的人 類或動物,其有任何一種已知的上皮細胞新生瘤,且較佳 為人類。二於預防方法時,受實驗者任為人類或動物,且 較佳為有得到上皮細胞新生瘤危險的人類。受實驗者可能 因曝露於致癌劑下、遺傳上較易得新生瘤等原因而有: 險。 新生瘤一詞包括良性及癌性腫瘤和生長。 -5- 本紙張尺度適财S S家標準(CNS) A4規格(210X297公着)
裝 訂 銳 1235060 五、發明説明(3 上述万法中,衍生自上皮細胞之瘤形成包括基細胞癌、 腺癌、大腸癌、前列腺癌、腎細胞癌及其它促使上皮細胞 遍及全身的癌。上皮細胞衍生癌較佳選自胃腸癌、肝癌、 膀胱癌、前列腺癌、子宮頸癌、肺癌、乳癌及皮膚癌/ 、用於預匕及治療衍生自上皮細胞之瘤形成之花生四缔酸 代謝中的環氧酶路徑抑制劑,可能由多種機制抑制酶活 性。例如,在此所述方法所用的抑制劑可藉由作為酶的酵 :物而直接阻斷酶活性。使用環氧酶_2選擇性抑制劑,可 高度有利於降低可由非NSAID造成之胃副作用,特別是在 預期有長時期預防藥治療時。 名柯"環氧酶一2抑制劑,,意指一種化合物可抑制環氧酶一2 而不會明顯抑制環氧酶q。其較佳包括化合物具有對環氧 S母-2<IC5G低〇·2微體積莫耳濃度,且亦有對環氧酶抑制 力除以對環氧酶-丨抑制力的選擇性比率至少5 〇,更佳為至 V 〇〇 Α化5物更佳具有環氧酶-1之IC5〇大於1微體積莫 耳濃度,大於10微體積莫耳濃度更好。 在此所提出的方法,係關於使用環氧酶_2抑制劑或其衍 生物於預防及治療上皮細胞衍生新生瘤。在較佳的具體實 施例中,環氧酶-2抑制劑係選擇自w〇/95 153 16的化合物。 環氧酶-2抑制劑係較佳選自式〗化合物:
R' -6 - 本紙張尺度適财8 g家鮮(CNS) Μ規格(摩297公爱)
I 1235060 A7 B7 五、發明説明(4 其中R2係選自氫、烷基、鹵烷基、烷氧羰基、氰基、氰 燒基、羧基、胺羰基、烷胺羰基、環烷胺羰基、芳胺羰 基、羧垸胺羰基、羧烷基、芳烷氧羰基烷胺羰基' 胺羰烷 基、燒氧羰基氰歸·基及經燒基; 其中R3係選自氫、烷基、氰基、羥烷基、環烷基、烷磺 酸基及函基;且 其中R4係選自芳烯基、芳基、環烷基、環婦基及雜環 基;其中R4可視情況在可取代位上以一個或多個選自鹵 基、烷硫基、烷磺醯基、氰基、硝基、函烷基、烷基、羥 基、婦基、羥烷基、羧基、環烷基、烷胺基、二烷胺基、 院氧羰基、胺羰基、烷氧基、!|烷氧基、胺磺醯基、雜環 基及胺基的基團取代; 或其藥學可接受鹽或衍生物。 一系列特別重要的化合物由式I化合物組成,其中R2係選 自氫、低碳數烷基、低碳數自烷基、低碳數烷氧羰基、氰 基、低碳數氰烷基、羧基 '胺羰基、低碳數烷胺羰基、低 碳數環烷胺羰基、芳胺羰基、低碳數羧烷胺羰基、低碳數 胺羰燒基、低碳數芳烷氧羰基烷胺羰基、低碳數羧烷基、 低碳數fe氧談基氰晞基及低碳數經燒基;其中R 3係選自 氫、低碳數烷基、氰基、低碳數羥烷基、低碳數環烷基、 低碳數磺醯基及鹵基;且其中R4係選自芳晞基、芳基、環 垸基、環烯基及雜環基;其中R4可在可取代位上視情況取 代以一個或多個選自函基、低碳數烷硫基、低碳數烷磺醯 基、氰基、硝基、低碳數_烷基、低碳數烷基、羥基、低 -7- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1235060 A7 B7 五、發明説明(5 碳數烯基、低碳數羥烷基、羥基、低碳數環烷基' 低碳數 烷胺基、低碳數雙烷胺基、低碳數烷氧羰基、胺羰基、低 石反數烷氧基、低碳數齒烷氧基、胺磺醯基、五員或六員雜 環基及胺基等基團;或取代以其藥學可接受鹽或衍生物。 式I化合物中特別重要的一族特定化合物,係由如下的化 合物、鹽學可接受鹽類及其衍生物組成: 4-[5-(4·氯苯基)-3-(三氟甲基)·_1Η•吡唑·卜基]苯磺醯 胺, 4-[5 -苯基- 3- (三氟甲基)-ϋ吡唑基]苯磺醯胺; 4 - [5 - (4 -氟苯基)-3-(三氟甲基)-1H -吡唑基]苯磺醯 胺; 4-[5-(4 -曱氧苯基)-3-(三氟甲基)_1H•吡唑“ ·基]苯磺醯 胺; 4-[5-(4 -氯苯基)-3-(二氟甲基)β1 η-吡唑基]苯磺醯 胺; 4-[5-(4 -甲苯基卜3-(三氟甲基)-} η-吡唑基]苯磺醯 胺; 4-[4-氯-5-(4-氯苯基)-3-(三氟甲基)·1Η-吡唑基]苯磺 醯胺; 4-[3-(二氟甲基)-5-(4 -甲苯基)-iH -吡唑基]苯磺醯 胺; ~ 4-[3*·(—氟甲基)-5 -苯基- lH-p比峻-1-基]苯績酿胺; 4-[3-(二氟甲基)-5-(4_甲氧苯基)-:l H_吡唑基]苯磺醯 胺; -8- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐)
裝 訂
l235〇6〇 A7 B7 五 發明説明(6 ) -氰基- 5- (4 -氟苯基)-1H-p比吃_ι_基]苯續臨胺; 4 - [ 3 -(二氟甲基)-5-(3_氟-4_甲氧苯基卜111_吡唑_1_基]苯 續酿胺; 、 4-[5-(3 -氟-4_甲氧苯基)-3-(三氟甲基)―丨^吡唑-丨·基]苯 續醯胺; 4-[4-氯-5-苯基-1H-吡唑-1-基;|苯磺醯胺; 4 [5-(4 -氯苯基)-3-(¾甲基)-ih -吡唑-1_基]苯續醯胺; 及 、 4-[5-(4-(N,N-二甲胺基)苯基卜3三氟甲基卜1H•吡唑一 1 ·基]苯續醯胺。 式I化合物中更特別重要的一族特定化合物,係由如下的 化合物、鹽學可接受鹽類及其衍生物組成: 4-[5-(4 -甲笨基)-3-(三氟甲基)-1Η_吡唑-丨-基]苯磺醯 胺; ' 4-[5-(4-氯苯基)-3_(二氟甲基)-丨心吡唑-丨-基^笨 胺;及 4-[5-(3-氟-4-甲氧苯基)-3-(二氟甲基)·_1Η_ 續醯胺。 基]冬 衍生物意指包含任何化合物,其結構似環氧酶 劑’或其具有實質相等的生物活性。、經由實例, 劑可包含但未限制於其前驅藥物。 使用於本發明方法中的化合物,可以自由Μ藥 文鉍加成鹽類的形式存在。名詞"藥學可接受鹽類"勺: 使用於形成鹼金族鹽類及形成自由酸或自由鹼=括常 刀17成鹽的 -9- 張尺度適财_家鮮(CNS) Α4規 1(21〇 X 297公|) 1235060 A7 B7 五、發明説明(7 ) 鹽類。該鹽的屬性並未苛求,只要其為藥學可接受的即 可。式I化合物的適合藥學可接受酸加成鹽類,可由無機或 有機酸中製備。該無機酸類的實例有氫氯酸、氫溴酸、氫 麟酸、硝酸、碳酸、硫酸及磷酸。適宜的有機酸可選自脂 肪酸、環脂肪酸、芳香酸、芳香脂肪酸、雜環酸、叛酸和 磺酸系列的有機酸,其實例有甲酸、乙酸、丙酸、丁二 酸、輕基乙酸、葡萄糖酸、乳酸、蘋果酸、酒石酸、擰檬 酸、抗壞血酸、乙四醇醛酸、順丁烯二酸、反丁晞二酸、 丙酮酸、天門冬氨酸、麵氨酸、苯甲酸、鄰-氨基苯甲酸、 甲磺醯胺酸、4 -羥基苯甲酸' 苯乙酸、苯乙醇酸、emb〇nic (pamoic) acid、甲磺酸、乙磺酸、苯磺酸、泛磺、2-羥基乙 續酸、甲苯橫酸、續胺酸、環己胺續酸、硬脂酸、蕩膠 酸、/3 -羥基丁酸、水楊酸、半乳糖酸及半乳糖醛酸。式j 化合物的適合藥學可接受驗加成鹽包括由鋁、約、經、 鎂、鉀、鈉及鋅形成的金屬鹽類,或由N,N,-二苯基乙晞 胺、氯化普魯卡因、?鹼、二乙醇胺、乙烯二胺、N —甲基 葡萄糖胺及普魯卡因形成的有機鹽類。所有這些鹽類可藉 由傳統方式’從相對的式I化合物以例如反應式I化合物與 適合的酸或鹼來製備。 材料與方法 細胞株:可使用下列細胞株:典型小細胞肺癌(SCLC)細 胞株 NCI-H209、NCI-H345 及 NCI-H510 ;變形 SCLC細胞株 NCI-N417及NCI-H82 ;大細胞癌細胞株NCI-H1155 ;腺癌細 -10- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1235060 A7 B7 五、發明就明(8 ) 胞株N C I-H23 ;及支氣管肺泡癌細胞株a 5 49、乳癌細胞株 MCF-7(美國型式組織培養,R0Ckville MD ; ATCC)及大腸 癌細胞株NCI-H630(ATCC)。所有的細胞可在RPMI -1640添 加5%胎牛血清(FBS)、青黴素及鏈黴素(Gibco公司出品, Grand Island ’紐約)之培養基中生長,並維持在37。〇下5 % 二氧化碳大氣壓的環境中。所有細胞株均未受黴漿菌污 染。 生長研究·使用一種修改過的(promega CellTiter 96®, Promega Madison,WI)半自動比色法 MTT (Nakanishi,et al.Exper· Cell Biol·,56,74-85(1988)),其藉由癌細胞將一 種四唑化合物還原,以分光光度計(54〇 nm)測定來計算細 胞數目。所有測試均在rPMI_1640培養基加運鐵蛋白(丁)1〇 公克/ ^:升、胰島素(1)5公克/毫升及硒 Chemicals,St· Louis,MO)下進行。種植密度為 1-2χι〇4 細胞/孔,且細胞生長5天。每個實驗均以平均光學密度校 正以背景+ /-標準變異係數報告。該環氧酶_2抑制劑應在劑 量2 0毫克/公斤下,對抑制癌細胞株的生長有效。 一種老鼠膀胱腫瘤模式,以如Grubbs等人 ks·,13,33-36(1993))所述的材料、試劑及程序進行。環 氧酶-2抑制劑的有效劑量應為2 0毫克/公斤。 一種老鼠乳房腫瘤模式,以如Grubbs等人(Anticancer ksy 15,7〇9-16(1995))所述的材料、試劑及程序進行。環 氧酶-2抑制劑的有效劑量應為2 0毫克/公斤。 衣 -11 - 1235060 五、發明説明(9 ) —種老鼠子宮頸及陰道癌模式,以如Arbeit等人(pr〇c
Sd·職’ 93 ’ 293〇_35(1996))所述的材料試劑及 心序進行。環氧酶_2抑制劑的有效劑量應為2()毫克/公斤。 —種大腸腺癌細胞模式,以如shiff等人(J. CHn Invest , 96,491_5G3(1995))所述的材料 '試劑及程序心。環氧 酶-2抑制劑的有效劑量應為2〇亳克/公斤。 、本發:的有效化合物,可以任何於此技藝中熟知的適合 万式投藥,較佳以藥學組合物修改的形式,加以所欲 的有效劑量。有效化合物及組合物可以如口服、血管内口 :、 :膜内、鼻内、支氣管内、皮下、肌肉内或局部(包括霧狀 吸入)方式投藥。 本發明可使用於預防或治療的目的。在此使用的方法及 組合物可單獨使用,或與其它在此技藝中所熟知的治療法 =預防或治療新生瘤。另—方面,在此所述的方法及组 .物可用作合併治療。經由實例,環氧酶_2抑制劑可單 與ί它抗瘤形成藥劑、其它生長抑制劑、其它藥物 或營養品合併施用。 "合併治療詞料義環氧酶_2抑制劑及其它藥劑的使 用時,係意指包括在-種養生法中每種藥劑的依序施用, 使提供樂物結合的有益效果;且亦意指包括同時合併投予 ,類樂劑’如在單一配方中含有固定比率的有效藥劑,或 士每種樂劑而有多重或分開的配方。本發明亦包本一種藥 =合二’用以合併預防及治療瘤形成,其包含治療有效 I的式1化合物,與至少—種藥學可接受載劑、佐藥或溶劑 -12- 本紙張尺度適财關家料7¾織格(摩挪公董) 1235060 A7 ---- B7 五、發明説明(1〇 ) (在此均指為”載劑”物質),及其它抗瘤形成劑或其它生長 抑制劑、其.它藥物或營養品。 若經口用藥,該藥學組合物可為如錠劑、膠囊、懸液或 液狀。該藥學組合物較佳以一個含特定量有效成份的劑量 規定單位之形式製造。該劑量規定單位之實例有膠囊、鍵 劑、粉劑、顆粒或懸浮液,併以熟知之添加物,如乳糖、 甘路糖醇、玉米澱粉或馬鈴薯澱粉;併以結合物,如結晶 纖維素、纖維素衍生物、阿拉伯膠、玉米澱粉或明膠;併 以分解物,如玉米澱粉、馬鈴薯澱粉或羧甲基纖維素鈉; 並併以潤滑劑,如滑石粉或硬脂酸鎂。該有效成份亦可經 >主射用藥,其注射用組合物可用如生理食鹽水、葡萄糖或 水作為適宜的載劑。 若經靜脈内、肌肉内、皮下或腹膜内用藥,該化合物可 與無菌水溶液結合,而該水溶液佳與受者血液等張。該配 方可藉由溶解固體有效成份於水中製備,而水中含有生理 可接受物質如氫化鈉、甘胺酸及其類似物,且有與生理狀 ’兄相容之緩衝酸鹼度以製造一種水溶液及使該溶液無菌。 ^配方可存在於單位或多次量容器如密封之小破璃瓶或藥 瓶中。 若新生瘤位於消化道中,該化合物可與於此技藝中熟知 的酸穩定、鹼不穩定之外膜調製,使其在較高酸驗度之小 腸中開始溶解。增強局部藥效及降低全身性攝取的配方為 較佳的。 適合非經腸的給藥法之配方,方便地含有有效化合物的 -13- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1235060 A7 B7 五、發明説明(11 無菌水溶性製備,其較佳製為等張。用於注射的製備,亦 可凋配將琢化合物懸浮化或乳化於非水溶性溶劑,如蔬菜 油、合成脂肪酸甘油酯、高級脂肪酸之酯類或丙二醇中。 局部使用的配方,包括已知的膠體、乳霜、油及其類似 物。於霧狀傳送時,該化合物可與已知之霧狀賦形劑如生 理食鹽水調配,並以市售喷霧器給藥。於脂肪酸中的配方 可用於增強生物相容性。霧狀傳送法是在預防肺上皮瘤形 成時,較佳的方法。 於直腸給藥時,該有效化合物可調配入栓劑中,該栓劑 使用在罜溫為固態而在體溫時融化或溶解的基質製成。常 用的基質包括可可油、甘油化明膠、氫化蔬菜油、不同分 子量的聚乙二醇與聚乙晞硬脂酸的脂肪醋。 規定劑量的形式及用量可輕易地藉由參考已知之新生瘤 治療或預防養生法建立。治療有效化合物的用藥量,及用 本發明的化合物和/或組合物於治療疾病之規定劑量養生 法,均視許多因素而定,包括受實驗者的年齡、體重、性 別及醫學狀況,及病情嚴重性、用藥途徑及頻率、特別化 合物疋使用、新生瘤之位置,和治療個體的藥動力學性 質,因此可有大幅地變異。若化合物用於局部及預防,會 較用於全身及治療方面的劑量來得少。該治療每當需要時 即可用藥,且由主治醫師決定需要的時間。在本技藝中較 佳之技術之一為對每個個體在該抑制劑之養生劑量或治療 有效量用藥方面予以最佳化。該藥學組合物可含有有效成 份在約0.1到2000毫克範圍内,較佳在約〇·5到5〇〇毫克範圍
裝 訂 -14 -
1235060 A7 B7 五、發明説明(12 ) 内,最佳在約1到200毫克之間。適宜的每天劑量為約0·01 到100毫克/公斤體重,較佳為約0.1到50毫克/公斤體重,最 佳為約1到20毫克/公斤體重。每天之劑量可用藥1到4次。 所有在此參考的專利均併入本文供參考。 雖然本發明已用特定實施例敘述,但該實施例之細節未 構成對本發明之限制。 藥理活性試驗及參考文獻 1. Reddy et al., Evaluation of Cyclooxygenase-2 Inhibitor for Potential Chemopreventive Properties in Colon Carcinogenesis. Cancer Research, 56, 4566-4569 (October 15, 1996). 2. Masferrer et al.5 Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitiors. Cancer Research 60, 1306-13 1 1 (March 13 2000). 3. Kawamori T., et al., Chemopreventive Activity of Celecoxib, a Specific Cyclooxygenase-2 Inhibitor, Against Colon Cancer. Cancer Research 58: 409-412 (1998). 4. Oshima et al, Suppression of Intestinal Polyposis in Ape ^^Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2). Cell VoL 87,803-809, November 29 (1996). 5. Boolbol et al·,Cylooxygenase-2 Overexpression and Tumor Formation are Blocked by Sulindac in a -15- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1235060 A7 ___ B7 五、發明説明(13 )
Murine Model of Familial Adenomatous Polyosis, Cancer Research 56: 2556-2560, (1996). 6. DA Talk Paper. FDA Approves Celebrex for New Indication. WWW.fda.gov/bbs/topics/ANSWERS/AN00992.html· (Demcember 23. 1999). a .鼠路易士肺癌模式 路易士肺癌物皮下植入C57BL/6公鼠之足趾。接著用4-[5-(4-氯苯基)-3 -(二氟甲基)-1H-吡唑-1 -基]苯磺醯胺處 理鼠。在第6天藥物以6毫克/公斤劑量加至飲水中。 每天藥物加至飲水最大容忍劑量為2毫克/公升。每個 化合物總共用10隻鼠測試。每二星期用體積描記器決定 腫瘤容積。在第32天注入癌細胞後測量這些化合物對腫 瘤生長之作用,如表1所示。藉計算與對照組比腫瘤大 小上差異算出抑制百分比之值。 表1 腫瘤容積(32天) 治療 抑制% 媒劑/對照組 0.00 C0X-2抑制劑 70.86 W 嗓美沙辛(indomethacin) 62.90 注射PC-3細胞(106細胞/ 0.2毫升30% matrigel)於 RPMI 1640培養基,至裸鼠背部。28天時,投與COX-2 b.PC-3 -16- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1235060 A7 ____B7 五、發明説明(14"") " 抑制劑4 - [ 5 - (4 -氯苯基)-3 -(二氟甲基)_ 1 η -吡唑-1 —基] 苯續醯胺(20毫克/公升/天於水)。45天後,測量 PGE2及ΤΧΒ2。在用COX-2抑制劑抑制55〇/〇腫瘤生長。 在經COX-2抑制劑處理動物中’ PGE2及ΤΧΒ〗含量減少 80 至 90%。
c.LNCaP 相似於PC-3結果,COX-2抑制劑4-[5-(4-氯苯芙)3 (二氟甲基)-1 Η - p比峻-1 -基]苯磺醯胺於飲水中劑量相當 於6毫克/公升/天,在第58天抑制55%腫瘤生長。 P S Α含量以西方墨點方鑑定出縮至約5〇〇/〇。 -17- 本紙張尺度適财® @家標準(CNS) A4規格(21GX297公爱) ' --------
Claims (1)
- 一種用於治療某個體上皮細胞 物,—,、、 也所何生贅瘤之醫藥組合 G括治療有效量之式I化合物, X 其中R2係C丨-6鹵烷基; 其中R3係氫;且 R4係苯基,其可視需要在可取代位置上經一個或多個 2自下列之基取代··自基、C1•旧硫基、U完橫驢 土、讯基、硝基、C"齒烷基、Cl.6烷基、羥基、C2_6 烯基、c丨·6羥烷基、羧基、。3_6環烷基、Ci_6烷胺基、 二C^6烷胺基、Cl·6烷氧羰基、胺羰基、Ci-6烷氧基、 c 1 -6鹵烷氧基、胺磺醯基、5或6員雜環基及胺基; 或其醫藥上可接受之鹽或衍生物,其限制條件為式J化 合物不為4-[5-(4-氯苯基)-3-(二氟甲基卜1H-吡唑_卜 基]苯磺醯胺及4-[5-(4-甲苯基)-3_(三氟甲基 吐-1-基]尽續酿胺。 2·根據申請專利範圍第丨項之醫藥組合物,其中該化合物係 選自下列化合物及其醫藥上可接受之鹽: 4·[5-(4-氯苯基)-3-(三氟甲基)_ih-吡唑-i_基]苯磺 醯胺; 4 - [ 5 -苯基· 3 ·(三氟甲基)-1 η -吡唑-1 _基]苯磺醯胺; -18 本紙張尺度適用中國國家標準(CNS) Α4規格(210X297公釐) 裝 訂 線 1235060 圍 範 利 專 請 中 .4 [ 5 - (4 -氟苯基)· 3 _ (三氟甲基)】H _吡唑-丨_基]苯磺 醯胺; 4_[5-(4_甲氧苯基)·3_(三氟甲基)_1H-吡唑基]苯 續醯胺; [4鼠5-(4 -氯私基)_3-(三氟曱基)β1Η-ρ比嗤-1·基] 苯續醯胺; 4_[3-(二氟甲基)-5-(4·甲苯基卜1Η_吡唑基]苯磺 醯胺; 4_[3-( —氟甲基)-5-(4_甲氧苯基卜1Η_吡唑基]苯 續醯胺; 4_[3-(二氟甲基)-5_(3_氟_4_甲氧苯基)“心吡唑“· 基]冬續酿胺; 4 [5-(3 -氟-4-甲氧苯基卜3-(三氟甲基)_1H-吡唑“_ 基]苯磺醯胺;及 4-[5-(4-(N,N-二甲胺基)苯基卜3-(三氟甲基)_1H-吡 嗤-1-基]苯績醯胺。 3·根據申請專利範圍第2項之醫藥組合物,其中該化合物為 4-[5-(3-氟-4 -甲氧苯基)_3-(二氟甲基卜1H_吡唑· ι •基] 苯橫酿胺,或其醫藥上可接受之鹽。 4·根據中請專利範圍第1項之醫藥組合物,其中瘤係選自結 陽直陽癌、胃陽癌、肝癌、膀晄癌、子宮頸癌、前列腺 癌、肺癌、乳癌及皮膚癌。 5· —種用於預防某個體之上皮細胞所衍生贅瘤之醫藥組合 物,戎瘤係選自胃腸癌、肝癌、膀脱癌、子宮頭痒 ^ -19 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1235060 as B8 C8 ------ 六、申請專利範圍 列腺癌、肺癌、乳癌及皮膚癌,包括治療有效量的式工化 合物,其中R2係C i _ 6鹵垸基; 其中R3係氫;且 R4係苯基,其可視需要在可取代位置上經一個或多個 選自下列t基取代··鹵基、c i · 6烷硫基、c i “烷磺醯 基、氰基、硝基、Cu鹵烷基、Cl-6烷基、羥基、c2-6 晞基、C ! · 6羥烷基、羧基、C 3 _ 6環烷基、c 1 _ 6烷胺基、 二…·6垸胺基、C1·6烷氧羰基、胺羰基、烷氧基、 Ci_6li、丨元氧基、胺績醯基、5或6員雜環基及胺基; 或其醫藥上可接受之鹽或衍生物,其限制條件為式j化 合物不為4-[5-(4-氯苯基)-3-(二氟甲基)-1H-吡唑_1-基]苯磺醯胺及4-[5·(4-甲苯基)-3-(三氟甲基广1H_吡 上* 1 -基]冬績酿胺。 6·根據申請專利範圍第5項之醫藥組合物,其中該化合物係 選自下列化合物及其醫藥上可接受之鹽: 4-[5-(4-氯苯基卜3_(三氟甲基卜1H-吡唑基]苯磺 醯胺; 4 [5 -苯基-3-(二氟甲基)_ιη·吡唑-1-基]苯續醯胺; -20-1235060 六、申請專利範圍 ABCD 經濟部中央標隼局員工消費合作社印製 -[5-(4 -氣苯基卜3_(三氟甲基)·1Η_吡唑·基 醯胺; ' 4-[5-(4 -甲氧苯基)_3_(三氟甲基)-1Η•吡唑基]苯 續Si胺; 4-[4 -氯-5-(4 -氯苯基)_3气三氟甲基卜1H_吡唑基 苯磺醯胺; & 4-[3-(二氟甲基)-5_(4-甲苯基)-1Η-吡唑基]苯磺 醯胺; ' 4-[3气二氟甲基)-5-(4_甲氧苯基)-1Η-吡唑-1-基]苯 磺醯胺; 4_[3-(二氟甲基卜5_(3 -氟-4_甲氧苯基)_1Η•吡唑 基]苯績酿胺; 4-[5-(3 -氟甲氧苯基卜3-(三氟甲基)“^^吡唑」· 基]苯續醯胺;及 4-[5-(4-(N,N -二甲胺基)苯基卜3-(三氟甲基卜1H -吡 峻· 1 -基]苯續醯胺。 7·根據申請專利範圍第5項之醫藥組合物,其中該化合物為 4-[5-(3-氟-甲氧苯基)-3-(二氟甲基)-ih-吡唑·ι·基] 苯磺醯胺,或其醫藥上可接受之鹽。 (請先閱讀背面之注意事項再填寫本頁) -21 - I纸張尺度適财關家標準(CNS〉(训aw公
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2849496P | 1996-10-15 | 1996-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI235060B true TWI235060B (en) | 2005-07-01 |
Family
ID=21843754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090122228A TWI235060B (en) | 1996-10-15 | 1997-10-14 | Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia |
Country Status (25)
Country | Link |
---|---|
EP (3) | EP1479385B1 (zh) |
JP (1) | JP2001503395A (zh) |
KR (1) | KR20000049138A (zh) |
CN (2) | CN100558356C (zh) |
AT (2) | ATE271385T1 (zh) |
AU (1) | AU742645B2 (zh) |
BR (1) | BR9712314A (zh) |
CA (1) | CA2267186C (zh) |
CZ (1) | CZ298022B6 (zh) |
DE (2) | DE69729946T2 (zh) |
DK (2) | DK0932402T3 (zh) |
ES (2) | ES2308068T3 (zh) |
HK (1) | HK1025518A1 (zh) |
HU (1) | HU227564B1 (zh) |
IL (3) | IL154501A0 (zh) |
NO (1) | NO326822B1 (zh) |
NZ (3) | NZ334921A (zh) |
PT (2) | PT932402E (zh) |
RO (1) | RO120172B1 (zh) |
RU (1) | RU2239429C2 (zh) |
SK (1) | SK284788B6 (zh) |
TR (1) | TR199900827T2 (zh) |
TW (1) | TWI235060B (zh) |
UA (1) | UA67732C2 (zh) |
WO (1) | WO1998016227A1 (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2223154A1 (en) | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US20040072889A1 (en) | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
US6887893B1 (en) | 1997-12-24 | 2005-05-03 | Sankyo Company, Limited | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia |
US6727238B2 (en) | 1998-06-11 | 2004-04-27 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
US6294558B1 (en) | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
PL349216A1 (en) * | 1998-12-23 | 2002-07-01 | Searle & Co | Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia |
US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
ATE425749T1 (de) * | 1999-01-27 | 2009-04-15 | Cornell Res Foundation Inc | Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs |
AU5873000A (en) * | 1999-06-24 | 2001-01-31 | Pharmacia Corporation | Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors forthe treatment of inflammation |
RU2268054C2 (ru) * | 1999-07-29 | 2006-01-20 | Амджен Инк. | Сочетанная терапия с использованием пентафторбензолсульфонамидов |
CN1543346A (zh) | 1999-11-22 | 2004-11-03 | ʷ��˿�������ȳ�ķ����˾ | 新化合物 |
EP1253921A4 (en) * | 2000-01-28 | 2004-10-13 | Merck & Co Inc | TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS |
GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
WO2001091856A2 (en) * | 2000-06-01 | 2001-12-06 | Pharmacia Corporation | Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
ATE300529T1 (de) | 2000-09-21 | 2005-08-15 | Smithkline Beecham Plc | Imidazolderivate als raf-kinase-inhibitoren |
WO2002039958A2 (en) | 2000-11-03 | 2002-05-23 | Tularik Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
ATE466577T1 (de) * | 2001-05-03 | 2010-05-15 | Cornell Res Foundation Inc | Behandlung von krankheiten, die durch hpv verursacht werden |
GB0112802D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0112810D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0119477D0 (en) | 2001-08-09 | 2001-10-03 | Glaxo Group Ltd | Pyrimidine derivatives |
ES2295428T3 (es) * | 2001-10-25 | 2008-04-16 | Novartis Ag | Combinaciones que comprenden un inhibidor selectivo de ciclooxigenasa-2. |
FR2835433B1 (fr) * | 2002-02-01 | 2006-02-17 | Richard Lab M | Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2 |
PL372962A1 (en) | 2002-04-08 | 2005-08-08 | Glaxo Group Limited | (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives |
JP2006500372A (ja) | 2002-08-19 | 2006-01-05 | グラクソ グループ リミテッド | 選択的cox−2阻害物質としてのピリミジン誘導体 |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
KR100484525B1 (ko) * | 2002-10-15 | 2005-04-20 | 씨제이 주식회사 | 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물 |
GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
PE20040844A1 (es) | 2002-11-26 | 2004-12-30 | Novartis Ag | Acidos fenilaceticos y derivados como inhibidores de la cox-2 |
CN1771235B (zh) * | 2003-02-11 | 2010-04-28 | 弗奈利斯(剑桥)有限公司 | 异噁唑化合物 |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
SG164378A1 (en) | 2005-02-17 | 2010-09-29 | Synta Pharmaceuticals Corp | Compounds for the treatment of proliferative disorders |
CA2600276C (en) | 2005-03-08 | 2013-01-08 | Mitsui Norin Co., Ltd | Polyphenol coxib combinations and methods |
AU2009272033B2 (en) * | 2008-07-17 | 2011-10-13 | Asahi Kasei Pharma Corporation | Nitrogenated heterocyclic compound |
WO2010022211A1 (en) * | 2008-08-22 | 2010-02-25 | Novartis Ag | Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity |
WO2017004274A2 (en) | 2015-06-29 | 2017-01-05 | Nantbioscience, Inc. | Compositions and methods of rit1 inhibition |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
US4012448A (en) | 1976-01-15 | 1977-03-15 | Stanford Research Institute | Synthesis of adriamycin and 7,9-epiadriamycin |
DE69224839T2 (de) | 1991-07-19 | 1998-10-08 | Monsanto Co | Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren. |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
ATE160345T1 (de) | 1993-01-15 | 1997-12-15 | Searle & Co | 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
CA2161789A1 (en) | 1993-05-13 | 1994-11-24 | Jacques Yves Gauthier | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
RO118291B1 (ro) * | 1993-11-30 | 2003-04-30 | Searle & Co | Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine |
US5475018A (en) | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
EP0772606A1 (en) | 1994-07-27 | 1997-05-14 | G.D. SEARLE & CO. | Substituted thiazoles for the treatment of inflammation |
US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5739166A (en) | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
US5596008A (en) | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
US5686470A (en) | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
ES2183935T3 (es) | 1995-02-13 | 2003-04-01 | Searle & Co | Isoxazoles sustituidos para el tratamiento de la inflamacion. |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
CA2223154A1 (en) * | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
EP0859779A4 (en) | 1995-08-31 | 2000-04-12 | Smithkline Beecham Corp | INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS |
DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Hoffmann La Roche | Matrix-metalloprotease Inhibitoren |
-
1997
- 1997-10-14 UA UA99052704A patent/UA67732C2/uk unknown
- 1997-10-14 NZ NZ334921A patent/NZ334921A/en not_active IP Right Cessation
- 1997-10-14 ES ES04011516T patent/ES2308068T3/es not_active Expired - Lifetime
- 1997-10-14 DK DK97911746T patent/DK0932402T3/da active
- 1997-10-14 NZ NZ506515A patent/NZ506515A/en not_active IP Right Cessation
- 1997-10-14 CN CNB2005100062282A patent/CN100558356C/zh not_active Expired - Fee Related
- 1997-10-14 EP EP04011516A patent/EP1479385B1/en not_active Expired - Lifetime
- 1997-10-14 RU RU99110192/15A patent/RU2239429C2/ru not_active IP Right Cessation
- 1997-10-14 IL IL15450197A patent/IL154501A0/xx not_active IP Right Cessation
- 1997-10-14 DK DK04011516T patent/DK1479385T3/da active
- 1997-10-14 TW TW090122228A patent/TWI235060B/zh not_active IP Right Cessation
- 1997-10-14 WO PCT/US1997/018670 patent/WO1998016227A1/en active IP Right Grant
- 1997-10-14 SK SK462-99A patent/SK284788B6/sk not_active IP Right Cessation
- 1997-10-14 JP JP51859198A patent/JP2001503395A/ja not_active Ceased
- 1997-10-14 HU HU9904221A patent/HU227564B1/hu not_active IP Right Cessation
- 1997-10-14 PT PT97911746T patent/PT932402E/pt unknown
- 1997-10-14 DE DE69729946T patent/DE69729946T2/de not_active Expired - Lifetime
- 1997-10-14 CZ CZ0117199A patent/CZ298022B6/cs not_active IP Right Cessation
- 1997-10-14 EP EP08159064A patent/EP1977749A1/en not_active Withdrawn
- 1997-10-14 IL IL12856897A patent/IL128568A0/xx not_active IP Right Cessation
- 1997-10-14 AU AU49048/97A patent/AU742645B2/en not_active Ceased
- 1997-10-14 CN CNB971987548A patent/CN1332661C/zh not_active Expired - Fee Related
- 1997-10-14 EP EP97911746A patent/EP0932402B1/en not_active Expired - Lifetime
- 1997-10-14 KR KR1019990703225A patent/KR20000049138A/ko not_active Application Discontinuation
- 1997-10-14 AT AT97911746T patent/ATE271385T1/de active
- 1997-10-14 ES ES97911746T patent/ES2224222T3/es not_active Expired - Lifetime
- 1997-10-14 RO RO99-00418A patent/RO120172B1/ro unknown
- 1997-10-14 CA CA002267186A patent/CA2267186C/en not_active Expired - Fee Related
- 1997-10-14 DE DE69738815T patent/DE69738815D1/de not_active Expired - Lifetime
- 1997-10-14 AT AT04011516T patent/ATE399547T1/de active
- 1997-10-14 BR BR9712314-5A patent/BR9712314A/pt not_active Application Discontinuation
- 1997-10-14 TR TR1999/00827T patent/TR199900827T2/xx unknown
- 1997-10-14 PT PT04011516T patent/PT1479385E/pt unknown
-
1999
- 1999-04-15 NO NO19991793A patent/NO326822B1/no not_active IP Right Cessation
-
2000
- 2000-08-04 HK HK00104885A patent/HK1025518A1/xx not_active IP Right Cessation
-
2001
- 2001-02-07 NZ NZ509755A patent/NZ509755A/xx not_active IP Right Cessation
-
2004
- 2004-12-16 IL IL16581604A patent/IL165816A0/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI235060B (en) | Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia | |
TW589174B (en) | Agent for treating high-risk impaired glucose tolerance | |
TWI259077B (en) | Combinations of drugs for the treatment of neoplastic disorders | |
DE69936150T2 (de) | Indomethacin-amidderivate zur antiangiogenen und/oder antitumorigen verwendung | |
US10449226B2 (en) | Combination | |
KR20140130179A (ko) | 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법 | |
EP1795194A2 (fr) | Utilisation d'un antagoniste des récepteurs CB1 associé à un bêta3-agoniste pour la préparation de médicaments utiles pour traiter l'appétence | |
JPH05507731A (ja) | 物質乱用障害の治療用医薬組成物 | |
TW200534852A (en) | 4-methylpyrazole formulations for inhibiting ethanol intolerance | |
US7834056B2 (en) | Pharmaceutical composition for gout | |
HU229150B1 (hu) | Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi mûködési zavarok kezelésére | |
TW200402301A (en) | Treatment of mucositis | |
CN109922801A (zh) | 甲硝唑和巴氯芬的混悬剂和稀释剂 | |
US6069147A (en) | Thermogenesis stimulating drugs | |
JP2004091473A (ja) | 色素沈着改善治療薬 | |
AU2002254947B2 (en) | Kappa opiate agonists for the treatment of bladder diseases | |
JP2001501958A (ja) | 性的能力障害治療用ピラゾリノン化合物 | |
TW383222B (en) | Pharmaceutical composition of bicycloheptane derivatives | |
KR102141519B1 (ko) | 치료 방법 | |
CN113613653A (zh) | 治疗边缘型人格障碍的方法 | |
TWI325317B (en) | Appetite-stimulating agents and remedies for anorexia | |
US11666643B1 (en) | Micronutrient combination to reduce blood pressure | |
TW577739B (en) | Pharmaceutical composition comprising celecoxib for maintaining circulation through fetal ductus arteriosus during treatment or prevention of preterm labor | |
CN104661681B (zh) | 包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合 | |
CN113797109A (zh) | 沙星类药物的抗衰老用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |